Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 140

1.

The value of participating in clinical trials: the whole is greater than the sum of its parts.

Zalcberg JR, Friedlander M.

Med J Aust. 2018 Nov 19;209(10):424-425. No abstract available.

PMID:
30428815
2.

Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCM™ system in a quaternary oncology centre.

Moloney M, Faulkner D, Link E, Rischin D, Solomon B, Lim AM, Zalcberg JR, Jefford M, Michael M.

Cancer Chemother Pharmacol. 2018 Nov;82(5):865-876. doi: 10.1007/s00280-018-3679-4. Epub 2018 Sep 3.

PMID:
30178115
3.

Rationale, Opportunities, and Reality of Biosimilar Medications.

Zalcberg JR.

N Engl J Med. 2018 Aug 16;379(7):694. doi: 10.1056/NEJMc1808348. No abstract available.

PMID:
30124273
4.

Potential solutions to improve the governance of multicentre health services research.

Evans SM, Zalcberg JR, Scarborough R.

Med J Aust. 2018 Aug 20;209(4):187. No abstract available.

PMID:
30107773
5.

Understanding and Communicating Measures of Treatment Effect on Survival: Can We Do Better?

Saad ED, Zalcberg JR, Péron J, Coart E, Burzykowski T, Buyse M.

J Natl Cancer Inst. 2018 Mar 1;110(3):232-240. doi: 10.1093/jnci/djx179.

PMID:
29933439
6.

"Mind the Gap" Revisited.

Zalcberg JR, Wonder M.

Semin Oncol. 2017 Oct;44(5):372-373. doi: 10.1053/j.seminoncol.2017.07.003. Epub 2017 Aug 2. No abstract available.

PMID:
29580438
7.

Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project.

Sjoquist KM, Renfro LA, Simes RJ, Tebbutt NC, Clarke S, Seymour MT, Adams R, Maughan TS, Saltz L, Goldberg RM, Schmoll HJ, Van Cutsem E, Douillard JY, Hoff PM, Hecht JR, Tournigand C, Punt CJA, Koopman M, Hurwitz H, Heinemann V, Falcone A, Porschen R, Fuchs C, Diaz-Rubio E, Aranda E, Bokemeyer C, Souglakos I, Kabbinavar FF, Chibaudel B, Meyers JP, Sargent DJ, de Gramont A, Zalcberg JR; Fondation Aide et Recherche en Cancerologie Digestive Group (ARCAD).

J Natl Cancer Inst. 2018 Jun 1;110(6):638-648. doi: 10.1093/jnci/djx253.

PMID:
29267900
8.

Do all services provided as part of a clinical trial require research ethics and governance review?

Kenner J, Zalcberg JR.

Intern Med J. 2017 Oct;47(10):1197-1199. doi: 10.1111/imj.13565. Review.

PMID:
28994255
9.

Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study.

Czito BG, Deming DA, Jameson GS, Mulcahy MF, Vaghefi H, Dudley MW, Holen KD, DeLuca A, Mittapalli RK, Munasinghe W, He L, Zalcberg JR, Ngan SY, Komarnitsky P, Michael M.

Lancet Gastroenterol Hepatol. 2017 Jun;2(6):418-426. doi: 10.1016/S2468-1253(17)30012-2. Epub 2017 Mar 27.

PMID:
28497757
10.

3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer.

Lutz MP, Zalcberg JR, Ducreux M, Aust D, Bruno MJ, Büchler MW, Delpero JR, Gloor B, Glynne-Jones R, Hartwig W, Huguet F, Laurent-Puig P, Lordick F, Maisonneuve P, Mayerle J, Martignoni M, Neoptolemos J, Rhim AD, Schmied BM, Seufferlein T, Werner J, van Laethem JL, Otto F.

Eur J Cancer. 2017 Jul;79:41-49. doi: 10.1016/j.ejca.2017.03.022. Epub 2017 Apr 29.

11.

Enough is enough … a call to action to improve ethical and governance review processes in Australia.

Evans SM, Zalcberg JR.

Intern Med J. 2016 Dec;46(12):1362-1364. doi: 10.1111/imj.13289. No abstract available.

PMID:
27981777
12.

Music's Relevance for People Affected by Cancer: A Meta-Ethnography and Implications for Music Therapists.

O'Callaghan CC, McDermott F, Reid P, Michael N, Hudson P, Zalcberg JR, Edwards J.

J Music Ther. 2016 Winter;53(4):398-429. Epub 2016 Nov 8.

PMID:
27980035
13.

Corrigendum to "2nd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer" [Eur J Cancer 63 (August 2016) 11-24].

Lutz MP, Zalcberg JR, Glynne-Jones R, Ruers T, Ducreux M, Arnold D, Aust D, Brown G, Bujko K, Cunningham C, Evrard S, Folprecht G, Gerard JP, Habr-Gama A, Haustermans K, Holm T, Kuhlmann KF, Lordick F, Mentha G, Moehler M, Nagtegaal ID, Pigazzi A, Pucciarelli S, Roth A, Rutten H, Schmoll HJ, Sorbye H, Van Cutsem E, Weitz J, Otto F.

Eur J Cancer. 2016 Nov;68:208-209. doi: 10.1016/j.ejca.2016.08.017. Epub 2016 Oct 4. No abstract available.

14.

TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer.

Ferraro D, Goldstein D, O'Connell RL, Zalcberg JR, Sjoquist KM, Tebbutt NC, Grimison P, McLachlan S, Lipton LL, Vasey P, Gebski VJ, Aiken C, Cronk M, Ng S, Karapetis CS, Shannon J; behalf of the the Australasian Gastro-Intestinal Trials Group.

Cancer Chemother Pharmacol. 2016 Aug;78(2):361-7. doi: 10.1007/s00280-016-3089-4. Epub 2016 Jun 22.

PMID:
27335026
15.

Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial.

Pavlakis N, Sjoquist KM, Martin AJ, Tsobanis E, Yip S, Kang YK, Bang YJ, Alcindor T, O'Callaghan CJ, Burnell MJ, Tebbutt NC, Rha SY, Lee J, Cho JY, Lipton LR, Wong M, Strickland A, Kim JW, Zalcberg JR, Simes J, Goldstein D.

J Clin Oncol. 2016 Aug 10;34(23):2728-35. doi: 10.1200/JCO.2015.65.1901. Epub 2016 Jun 20.

16.

Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer.

Lutz MP, Zalcberg JR, Glynne-Jones R, Ruers T, Ducreux M, Arnold D, Aust D, Brown G, Bujko K, Cunningham C, Evrard S, Folprecht G, Gerard JP, Habr-Gama A, Haustermans K, Holm T, Kuhlmann KF, Lordick F, Mentha G, Moehler M, Nagtegaal ID, Pigazzi A, Pucciarelli S, Roth A, Rutten H, Schmoll HJ, Sorbye H, Van Cutsem E, Weitz J, Otto F.

Eur J Cancer. 2016 Aug;63:11-24. doi: 10.1016/j.ejca.2016.04.010. Epub 2016 May 30. Erratum in: Eur J Cancer. 2016 Nov;68:208-209.

17.

Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer.

Liu G, Tu D, Lewis M, Cheng D, Sullivan LA, Chen Z, Morgen E, Simes J, Price TJ, Tebbutt NC, Shapiro JD, Jeffery GM, Mellor JD, Mikeska T, Virk S, Shepherd LE, Jonker DJ, O'Callaghan CJ, Zalcberg JR, Karapetis CS, Dobrovic A.

Clin Cancer Res. 2016 May 15;22(10):2435-44. doi: 10.1158/1078-0432.CCR-15-0414.

18.

Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study.

Folprecht G, Pericay C, Saunders MP, Thomas A, Lopez Lopez R, Roh JK, Chistyakov V, Höhler T, Kim JS, Hofheinz RD, Ackland SP, Swinson D, Kopp M, Udovitsa D, Hall M, Iveson T, Vogel A, Zalcberg JR.

Ann Oncol. 2016 Jul;27(7):1273-9. doi: 10.1093/annonc/mdw176. Epub 2016 Apr 18.

PMID:
27091810
19.

Serious adverse event reporting in investigator-initiated clinical trials.

Wallace S, Myles PS, Zeps N, Zalcberg JR.

Med J Aust. 2016 Apr 4;204(6):231-3.

PMID:
27031396
20.

Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas.

Casali PG, Le Cesne A, Poveda Velasco A, Kotasek D, Rutkowski P, Hohenberger P, Fumagalli E, Judson IR, Italiano A, Gelderblom H, Adenis A, Hartmann JT, Duffaud F, Goldstein D, Broto JM, Gronchi A, Dei Tos AP, Marréaud S, van der Graaf WT, Zalcberg JR, Litière S, Blay JY.

J Clin Oncol. 2015 Dec 20;33(36):4276-83. doi: 10.1200/JCO.2015.62.4304. Epub 2015 Nov 16.

PMID:
26573069
21.

Oxaliplatin/5-fluorouracil-based adjuvant chemotherapy as a standard of care for colon cancer in clinical practice: Outcomes of the ACCElox registry.

Park YS, Ji J, Zalcberg JR, El-Serafi M, Buzaid A, Ghosn M.

Asia Pac J Clin Oncol. 2015 Dec;11(4):334-42. doi: 10.1111/ajco.12409. Epub 2015 Oct 15.

PMID:
26471890
22.

Clinical utility of ramucirumab in advanced gastric cancer.

Chan MM, Sjoquist KM, Zalcberg JR.

Biologics. 2015 Sep 22;9:93-105. doi: 10.2147/BTT.S62777. eCollection 2015. Review.

23.

An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer.

Lee YC, Michael M, Zalcberg JR.

Expert Opin Investig Drugs. 2015;24(10):1307-20. doi: 10.1517/13543784.2015.1070483. Epub 2015 Jul 27. Review.

PMID:
26212373
24.

Views of Australian Medical Oncologists Regarding the Use of Mismatch Repair Status to Assist Adjuvant Chemotherapy Recommendations for Patients With Early-Stage Colon Cancer.

Loh KW, Michael M, Zalcberg JR, Jefford M.

Clin Colorectal Cancer. 2015 Sep;14(3):192-7. doi: 10.1016/j.clcc.2015.03.001. Epub 2015 Apr 1.

PMID:
26002619
25.

Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17.

Brulé SY, Jonker DJ, Karapetis CS, O'Callaghan CJ, Moore MJ, Wong R, Tebbutt NC, Underhill C, Yip D, Zalcberg JR, Tu D, Goodwin RA.

Eur J Cancer. 2015 Jul;51(11):1405-14. doi: 10.1016/j.ejca.2015.03.015. Epub 2015 May 12.

PMID:
25979833
26.

Accepting risk in the acceleration of drug development for rare cancers.

Ashley D, Thomas D, Gore L, Carter R, Zalcberg JR, Otmar R, Savulescu J.

Lancet Oncol. 2015 Apr;16(4):e190-4. doi: 10.1016/S1470-2045(14)71153-2.

PMID:
25846099
27.

Gastric cancer: past progress and present challenges.

Sjoquist KM, Zalcberg JR.

Gastric Cancer. 2015 Apr;18(2):205-9. doi: 10.1007/s10120-014-0437-0. Epub 2014 Oct 26. No abstract available.

PMID:
25344928
28.

Broken doctor-patient relationships: why won't they listen?

Jefford M, Zalcberg JR.

Med J Aust. 2014 Sep 15;201(6):347-9. No abstract available.

PMID:
25222460
29.

Bespoke treatment: drivers beware!

Pattison S, Zalcberg JR.

Asia Pac J Clin Oncol. 2014 Dec;10(4):378-80. doi: 10.1111/ajco.12265. Epub 2014 Aug 25.

PMID:
25155963
30.

Sound continuing bonds with the deceased: the relevance of music, including preloss music therapy, for eight bereaved caregivers.

O'Callaghan CC, McDermott F, Hudson P, Zalcberg JR.

Death Stud. 2013 Feb;37(2):101-25.

PMID:
24520844
31.

The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17.

Sommeijer DW, Karapetis CS, Zalcberg JR, Tu D, Jonker DJ, Simes J, Tebbutt N, Yip D, Price TJ, O'Callaghan CJ.

Acta Oncol. 2014 Jul;53(7):877-84. doi: 10.3109/0284186X.2013.879202. Epub 2014 Feb 5.

PMID:
24495042
32.

Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer.

Jonker DJ, Karapetis CS, Harbison C, O'Callaghan CJ, Tu D, Simes RJ, Malone DP, Langer C, Tebbutt N, Price TJ, Shapiro J, Siu LL, Wong RP, Bjarnason G, Moore MJ, Zalcberg JR, Khambata-Ford S.

Br J Cancer. 2014 Feb 4;110(3):648-55. doi: 10.1038/bjc.2013.753. Epub 2013 Dec 12.

33.

"A quiet still voice that just touches": music's relevance for adults living with life-threatening cancer diagnoses.

O'Callaghan CC, McDermott F, Michael N, Daveson BA, Hudson PL, Zalcberg JR.

Support Care Cancer. 2014 Apr;22(4):1037-47. doi: 10.1007/s00520-013-2059-1. Epub 2013 Nov 28.

PMID:
24287507
34.

PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17.

Karapetis CS, Jonker D, Daneshmand M, Hanson JE, O'Callaghan CJ, Marginean C, Zalcberg JR, Simes J, Moore MJ, Tebbutt NC, Price TJ, Shapiro JD, Pavlakis N, Gibbs P, Van Hazel GA, Lee U, Haq R, Virk S, Tu D, Lorimer IA; NCIC Clinical Trials Group and the Australasian Gastro-Intestinal Trials Group.

Clin Cancer Res. 2014 Feb 1;20(3):744-53. doi: 10.1158/1078-0432.CCR-13-0606. Epub 2013 Nov 11.

35.

The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: results from the Australasian phase III MAX study.

Carter HE, Zannino D, John Simes R, Schofield DJ, Howard K, Zalcberg JR, Price TJ, Tebbutt NC.

Eur J Cancer. 2014 Feb;50(3):535-43. doi: 10.1016/j.ejca.2013.09.028. Epub 2013 Nov 8.

PMID:
24215848
36.

Quality of life in patients with K-RAS wild-type colorectal cancer: the CO.20 phase 3 randomized trial.

Ringash J, Au HJ, Siu LL, Shapiro JD, Jonker DJ, Zalcberg JR, Moore MJ, Strickland A, Kotb R, Jeffery M, Alcindor T, Ng S, Salim M, Sabesan S, Easaw JC, Shannon J, El-Tahche F, Walters I, Tu D, O'Callaghan CJ; NCIC Clinical Trials Group; Australasian Gastrointestinal Trials Group.

Cancer. 2014 Jan 15;120(2):181-9. doi: 10.1002/cncr.28410. Epub 2013 Oct 11.

37.

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.

Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, Dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Zalcberg JR, Chau I, Campbell W, Sivanandan C, Pikiel J, Koshiji M, Hsu Y, Liepa AM, Gao L, Schwartz JD, Tabernero J; REGARD Trial Investigators.

Lancet. 2014 Jan 4;383(9911):31-39. doi: 10.1016/S0140-6736(13)61719-5. Epub 2013 Oct 3.

PMID:
24094768
38.

Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial.

Siu LL, Shapiro JD, Jonker DJ, Karapetis CS, Zalcberg JR, Simes J, Couture F, Moore MJ, Price TJ, Siddiqui J, Nott LM, Charpentier D, Liauw W, Sawyer MB, Jefford M, Magoski NM, Haydon A, Walters I, Ringash J, Tu D, O'Callaghan CJ.

J Clin Oncol. 2013 Jul 1;31(19):2477-84. doi: 10.1200/JCO.2012.46.0543. Epub 2013 May 20.

PMID:
23690424
39.

Reducing clinical trial monitoring resource allocation and costs through remote access to electronic medical records.

Uren SC, Kirkman MB, Dalton BS, Zalcberg JR.

J Oncol Pract. 2013 Jan;9(1):e13-6. doi: 10.1200/JOP.2012.000666.

40.

A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer.

Mellor JD, Brown MP, Irving HR, Zalcberg JR, Dobrovic A.

J Hematol Oncol. 2013 Jan 4;6:1. doi: 10.1186/1756-8722-6-1. Review.

41.

Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17.

Vickers MM, Karapetis CS, Tu D, O'Callaghan CJ, Price TJ, Tebbutt NC, Van Hazel G, Shapiro JD, Pavlakis N, Gibbs P, Blondal J, Lee U, Meharchand JM, Burkes RL, Rubin SH, Simes J, Zalcberg JR, Moore MJ, Zhu L, Jonker DJ.

Ann Oncol. 2013 Apr;24(4):953-60. doi: 10.1093/annonc/mds577. Epub 2012 Nov 8.

PMID:
23144444
42.

Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumors.

Kee D, Zalcberg JR.

Ther Adv Med Oncol. 2012 Sep;4(5):255-70. doi: 10.1177/1758834012450935.

43.

Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer.

Lutz MP, Zalcberg JR, Ducreux M, Ajani JA, Allum W, Aust D, Bang YJ, Cascinu S, Hölscher A, Jankowski J, Jansen EP, Kisslich R, Lordick F, Mariette C, Moehler M, Oyama T, Roth A, Rueschoff J, Ruhstaller T, Seruca R, Stahl M, Sterzing F, van Cutsem E, van der Gaast A, van Lanschot J, Ychou M, Otto F; First St Gallen EORTC Gastrointestinal Cancer Conference 2012 Expert Panel.

Eur J Cancer. 2012 Nov;48(16):2941-53. doi: 10.1016/j.ejca.2012.07.029. Epub 2012 Aug 23.

PMID:
22921186
44.

The role of biological agents in the resection of colorectal liver metastases.

Nordlinger B, Adam R, Arnold D, Zalcberg JR, Gruenberger T.

Clin Oncol (R Coll Radiol). 2012 Aug;24(6):432-42. doi: 10.1016/j.clon.2012.01.002. Review.

PMID:
22794325
45.

Dose optimization of tyrosine kinase inhibitors to improve outcomes in GIST.

Zalcberg JR, Desai J.

Asia Pac J Clin Oncol. 2012 Mar;8(1):43-52. doi: 10.1111/j.1743-7563.2011.01491.x. Epub 2012 Feb 20. Review.

PMID:
22369443
46.

Comparative effectiveness research--a proposal for a new NHMRC funding stream.

Zalcberg JR.

Med J Aust. 2012 Jan 16;196(1):22-3.

PMID:
22256921
47.

Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis.

Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, Gebski V; Australasian Gastro-Intestinal Trials Group.

Lancet Oncol. 2011 Jul;12(7):681-92. doi: 10.1016/S1470-2045(11)70142-5. Epub 2011 Jun 16.

PMID:
21684205
48.

A survey of reimbursement practices of private health insurance companies for pharmaceuticals not covered under the Pharmaceutical Benefits Scheme 2008.

Lingaratnam SM, Kirsa SW, Mellor JD, Jackson J, Crellin W, Fitzsimons M, Zalcberg JR.

Aust Health Rev. 2011 May;35(2):204-10. doi: 10.1071/AH10894.

PMID:
21612735
49.

Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer.

Day FL, Leong T, Ngan S, Thomas R, Jefford M, Zalcberg JR, Rischin D, McKendick J, Milner AD, Di Iulio J, Matera A, Michael M.

Br J Cancer. 2011 Jan 18;104(2):265-71. doi: 10.1038/sj.bjc.6606051. Epub 2010 Dec 14.

50.

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.

De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Van Cutsem E, O'Callaghan CJ, Khambata-Ford S, Zalcberg JR, Simes J, Karapetis CS, Bardelli A, Tejpar S.

JAMA. 2010 Oct 27;304(16):1812-20. doi: 10.1001/jama.2010.1535.

PMID:
20978259

Supplemental Content

Loading ...
Support Center